Skip to main content
Accessibility
Search
Understanding FA
What is Friedreich’s ataxia?
Signs and Symptoms
Journey to an FA Diagnosis
Genetics of FA
Treating and Managing FA
Newly Diagnosed
What You Need to Know
Connect with Others in the Community
Managing FA
Clinical Management Guidelines
Assembling a Care Team
Treatment for FA
Approved Treatments
For Healthcare Professionals
Terms to Know (Glossary)
Research
Grant Program
Grant Application Process
Grant Types
FARA Funded Grants
Grant Priorities
Opportunities for Young Investigators
Research Resources
Research and Drug Development Tools
Scientific Conferences
Regulatory Interactions
Research Initiatives
FA Global Clinical Consortium
FARA Directed Research
Institutional Supported Programs
Drug Development Pipeline
Participate in Research
Clinical Trial Finder
Understanding Clinical Trials
Understanding Genetic Therapies
Tissue Donation Programs
Get Involved
Fundraising and Events
rideATAXIA
Energy Ball
Team FARA
Grassroots Fundraising
Participate in Research
Clinical Trial Finder
Understanding Clinical Trials
Understanding Genetic Therapies
Connect with the Community
Ways to Give
Advocate
Advocacy Initiatives
Become an Advocate
Advocacy Partnerships
FARA Ambassador Program
Meet the Ambassadors
Ambassador Portal
Corporate Partnership
Events & News
Events Calendar
News
Blog
Why We Exist
Our History
Our Mission
Our Strategic Plan
Our Community
FARA Ambassadors
Meet the Community
Memorials
FARA Staff
Board of Directors
Scientific Advisory Board
Donate
News & Blog
News & Blog
|
Feb 4 2025
CAP-004
|
May 17 2024
ASP2016
|
Mar 19 2024
NAD+ and Exercise in FA
|
Mar 19 2024
Leriglitazone (MIN-102)
|
Mar 19 2024
AVB-202-TT Gene Therapy
|
Mar 19 2024
AAV Gene Editing
|
Mar 19 2024
Elamipretide (Brand Name FORZINITY™ for Barth Syndrome)
|
Mar 19 2024
TAK-831
|
Mar 19 2024
RT001
|
Mar 19 2024
Resveratrol
|
Mar 19 2024
Pioglitazone
|
Mar 19 2024
OXIGON (OX1 aka SHP622, VP20629)